natgillin/translations-raw huggingface dataset:
A method for treating and/or preventing pain, comprising administering a pharmacologically effective amount of a compound or a pharmacologically acceptable salt thereof according to any one of claims 1 to 16 to a mammal. 
Uporaba spoja ili njegove farmakološki prihvatljive soli prema bilo kojem od zahtjeva 1 do 6 za proizvodnju farmaceutskog pripravka za liječenje i/ili prevenciju fibromialgije. hept-3-en-6-iljoctena kiselina; hept-3-en-6-iljoctena kiselina; lo
SEQ ID NO: 5 corresponding to Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Gly-(Lys)15-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg, and a pharmaceutically or cosmetically acceptable carrier and/or diluent. 
Farmaceutski ili kozmetički pripravak koji sadrži peptid, naznačen time, što se peptid sastoji od aminokiseline SEQ ID NO: 5 koja odgovara Arg-Lys-Lys-Arg-Arg-Gln-Arg-ArgArg-Gly-(Lys)15-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg, i farmaceutski ili kozmetički prihvatljivog nosača i/ili otapala.
The method of claim 10, wherein the subject is a human. The method of claim 10, wherein the arthritis is osteoarthritis, trauma traumatic arthritis, or autoimmune arthritis. 
Farmaceutski sastav za uporabu prema zahtjevu 12, ili polipeptid za uporabu prema zahtjevu 15, naznačen time, da se kod artritisa radi o osteoartritisu, traumatskom artritisu, ili autoimunom artritisu.
represents a hydrogen atom; and 
R predstavlja vodikov atom; i
4, 6 and 8, the level of the apex of the ring bead (15) is sloped downwards toward the next adjacent portion of the peripheral wall (5) in accordance with the slope of the upper surface of the elevation (18) with reference to the radial level that is vertical to axis (14). 
Poklopac limenke u skladu s patentnim zahtjevom 7, naznačen time što ploča poklopca (2) uključuje područje (19) koje okružuje prstenastu stijenku (11), koja je tako nagnuta da odgovara gornjoj površini podloge uzvišenja (18).
After the reinforcement package 2 and the preformed air-tight covering 3, inclusive of the channel parts 7, have been laid in the mold (Fig. 2), the course of the process is as has been set out hereinabove with reference to Figs. 1a-d. 
Kad se tijelo za ojačanje 2 i prethodno oblikovan neprodušan pokrov 3, uključiv i dijelove kanala 7, stave u kalup (slika 2), tijek postupka je isti kao što je gore opisano u svezi sa slikama 1a-d.
The phosphoric acid solution can be added to a solution of the amine, or the addition can be performed in the reverse direction. 
Otopina fosforne kiseline može se dodati u otopinu amina, ili se dodavanje može izvoditi u obrnutom smjeru.
In addition, in the present invention, it is preferable that the phosphoric acid-activating compound is UMP-imidazolide, and the phosphoric acid compound is UTP or a UTP salt. 
Postupak proizvodnje u skladu s patentnim zahtjevom 1, naznačen time, da je spoj za aktivaciju fosforne kiseline UMP-imidazolid, a spoj fosforne kiseline je sol UTP-a.
A pharmaceutical composition containing the compound, a pharmaceutically acceptable salt or a hydrate thereof according to any one of claims 1 to 4 as an active ingredient. 
Farmaceutski sastav koji sadrži spoj, farmaceutski prihvatljiva sol ili njihov hidrat temeljem bilo kojeg od prethodnih zahtjeva 1 do 4 kao aktivnu tvar.
A microencapsulated bacterial consortium, according to claim 7, comprising: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) from 40 to 60% of isolated protein from milk serum with 90% protein; e) from 10 to 20% of maltodextrin with a dextrose equivalent of 10; f) from 20 to 80% arabic gum; g) from 1 to 10% of maguey honey; and h) trehalose; in combination with 0.005 to 0.03% of a proteolytic enzyme of bacterial origin and 0.001 to 0.02% of a proteolytic enzyme of fungal origin. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 8, koji sadrži: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis NTCC 27652; c) Lactobacillus brevis ATCC 14869; d) od 40 do 60 % izoliranog proteina 1z mliječnog seruma s 90 % proteina; e) od 10 do 20 % maltodekstrina s ekvivalentom dekstroze od 10; f) od 20 do 80 % gume arabike; g) od 1 do 10 % meda agave; i h) trehalozu; u kombinaciji s 0,005 do 0,03 % proteolitičkog enzima bakterijskog porijekla 1 0,001 do 0,02 % proteolitičkog enzima gljivičnog porijekla.
A pharmaceutical composition comprising the polynucleotide according to claim 2, wherein the polynucleotide is provided in a viral vector. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 7, naznačen time što se polinukleotid nalazi u virusnom vektoru.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, ipconazole, prothioconazole, tebuconazole, epoxiconazole, propiconazole, and cyproconazole. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
Polyurethane (PU) and other top coatings such as PU acrylates, epoxy acrylates, polyester acrylates, polyether acrylates, silicone acrylates etc are widely used as surface reinforcement on plastic floorings, for residential use as well as for commercial use. 
Poliuretan (PU) i drugi gornji slojevi kao što su PU akrilati, epoksidni akrilati, poliester akrilati, polieter akrilati, silikonski akrilati itd. naširoko se primjenjuju kao površinsko pojačanje na plastičnim podovima, za stambene kao i za komercijalne svrhe.
fragrance in an amount of from 2% to 4% by weight of the total composition 
miris u količini od 2% do 4 masenih% ukupnog pripravka
and R2, together with the carbon atom to which they are attached, form a divalent C3-C8-cycloaliphatic group; 
R' i R? zajedno s ugljikovim atomom, na koji su oni povezani, tvore dvovalentnu C;-Cg-cikloalifatsku skupinu;
dissolved or suspended in at least one organic solvent, with tetrafluoroethylene in the presence of water and an inorganic base to form said Tetraconazole having formula (I) or one of its optically active isomers. 
(II) otopljenog ili suspendiranog u najmanje jednom organskom otapalu, s tetrafluoretilenom u prisutnosti vode i anorganske baze kako bi se dobilo navedeni tetrakonazol formule (1) ili jedan od njegovih optički aktivnih izomera.
is an alkyl group having a carbon number of 1 to 6 optionally having substituent(s) or an aralkyl group optionally having substituent(s); 
R/ je alkilna skupina koja ima broj ugljika od 1 do 6 opcijski sa supstituentima ili je aralkil-skupina koja opcijski ima supstituente;
culturing the one or more cells in the copper supplemented cell culture media such that rVWF is expressed and excreted from the cells into a culture supernatant and the NH4+content of the cell culture supernatant is maintained at a concentration below 4 mM or below 10 mM; and recovering at least a portion of the culture supernatant, wherein the recovered supernatant has a rVWF specific ristocetin cofactor activity of at least 30 mU/ug rVWF. 
(d) uzgoja jedne ili više stanica u mediju za uzgoj stanica kompletiranom bakrom, tako da se rvWrF eksprimira i izlučuje iz stanica u supernatant kulture, gdje se sadržaj NHL* u supernatantu kulture stanica održava u koncentraciji ispod # mM; i (e) prikupljanja u najmanju ruku dijela supernatanta kulture, gdje prikupljeni supernatant ima aktivnost ristocetinskog sučimbenika specifičnu za rVWF od najmanje 30 mU/ug rVWF.
an offset decoding section configured to decode an offset which is restricted to a value within the offset value range; and an offset adder configured to add the offset to the pixel value of a pixel of a unit area of the deblocked decoded image wherein the offset attribute setting section is configured to set the offset bit depth to be equal to a bit depth of the pixel values in a case that the bit depth of the pixel values is ten or smaller, and the offset attribute setting section is configured to set the offset bit depth to be ten in a case that the bit depth of the pixel values is eleven or greater, wherein the offset attribute setting section is configured to set a maximum offset value range to be 2(the offset bit depth-K)-1−1 or smaller. 
Uređaj za filtriranje slike za primanje deblokirane dekodirane slike i dodavanje offset vrijednosti piksela za svaki piksel jedinične površine deblokirane dekodirane slike koja je sastavljena od mnoštva jediničnih površina, koji sadrži: jedinicu za offset dekodiranje konfiguriranu da dekodira offset koji je ograničen na raspon vrijednosti offseta; i jedinicu za filtriranje konfiguriranu za dodavanje offset vrijednosti piksela za svaki piksel jedinične površine deblokirane dekodirane slike naznačen time što je jedinica za postavljanje atributa offseta konfigurirana za postavljanje dubine bita offseta SAO_DEPTH i raspona offset vrijednosti prema kodiranim podacima, pri čemu je maksimalna duljina bita koja predstavlja raspon offset vrijednosti jednaka SAO_DEPTH - K i vrijednost K je jednaka 4.
The solid oral extended release pharmaceutical dosage form of claim 36, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 28, naznačen time da je gustoća formulacije matrice s produljenim otpuštanjem a jednaka ili niža od 1.20 g/em', poželjno jednaka ili niža od 1.19 g/cm'.
providing the connection element for the dental implant, the connection element having a first connection portion operable to connect to the dental implant, and a second connection portion operable to connect to the dental prosthesis; 
pripremu elementa za povezivanje (L) na zubni implantat, spomenuti element za povezivanje (L) ima prvi dio za povezivanje (3) na spomenuti zubni implantat, i spomenuti drugi dio za povezivanje (4) na zubnu protezu,
The method of claim 21, wherein the pinanediol boronic ester is obtained by trans-esterification of a pinacol boronate of formula (XXXIII): 
te opcionalno, pritom se pinandiol ester boronske kiseline dobiva putem trans-esterifikacije pinakol boronata formule (XXXIII):
Aspect: Method according to one of the preceding aspects, wherein the further mobile communication technology is a technology according one of the IEEE-802.11-family of mobile communication standards. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu je druga mobilna komunikacijska tehnologija, tehnologija prema jednom iz IEEE 802.11-seta standarda za mobilnu komunikaciju.
adding the ß-cyclodextrin to the first mixture to form a second mixture; 
dodavanja B-ciklodekstrina u prvu smjesu kako bi se dobilo drugu smjesu;
Three subtypes, which are designated as PPARa, PPARY and PPARδ are found in species ranging from Xenopus to humans. 
U vrstama koje se kreću od gubavice Xenopus do ljudi nađena su tri podtipa, naznačena kao PPARa, PPARy i PPARS$,.
The use of a combination of any one of claims 1 to 6 for the manufacture of a medicament for the treatment or prevention of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage. 
Upotreba kombinacije prema bilo kojem od patentnih zahtjeva 1-10 za proizvodnju lijeka za liječenje ili prevenciju karcinoma, upalnih bolesti, reperfuzijskih povreda, ishemijskih stanja, moždanog udara, bubrežne insuficijencije, kardiovaskularnih bolesti, vaskularnih bolesti različitih od kardiovaskularnih bolesti, dijabetesa, neurodegenerativnih bolesti, retrovirusnih infekcija, oštećenja retine ili starenja kože i oštećenja kože izazvanih UV-zračenjem.
The method according to claim 1 wherein dyslipidemia is mixed dyslipidemia. The method according to claim 1 wherein the cardiovascular diseases derived from heart rhythm disorders are chosen among auricular and/or ventricular arrhythmia, tachycardia, fibrillation and/or electrical conduction defects induced by myocardial infarction. 
Ester dokosaheksanske kiseline prema patentnom zahtjevu 1 ili 2, piridin-3-ilmetil dokosaheksanoat ili farmaceutski pripravak prema patentnom zahtjevu 8, naznačen time da je za upotrebu prema patentnom zahtjevu 10, pri čemu su kardiovaskularne bolesti izvedene od poremećaja ritma srca sljedeće: aurikularna i/ili ventrikularna aritmija, tahikardija, fibrilacija i/ili poremećaj električne vodljivosti induciran infarktom miokarda.
In one aspect, the present invention provides compounds of formula (I): wherein each of R1, R1' and R3 represents hydrogen; 
U jednom aspektu ovog izuma osiguravaju se spojevi formule (Ia) i formule (Ib): (R'%) gdje:
In another presently preferred construction and arrangement, the invert arm is coupled to the first electric motor through a plurality of gears. 
U jednom drugom trenutno preferiranom konstrukcijskom rješenju i izvedbi, invertirajuća ruka je spojena na prvi elektromotor preko nekoliko zupčanika.
The preparation of a compound of formula (3), as described herein, is described for example, in Method 1 of Subsection C-1 in WO2008/083967. 
R1 vodikova ili dušikova zaštitna grupa; i R4 je odabran od alkila, arila i arilalkila; reakcijom spoja sa formulom (3), ili njegove soli,
converting a medium containing an L-arabinose source with a cell according to claim 11, which converts L-arabinose to produce the metabolization product, 
(a)prevođenja medija koji sadrži izvor L-arabinoze stanicom u skladu s patentnim zahtjevom 11, koja prevodi Larabinozu u metabolički produkt,
The method of claim 16, wherein: CDRs 1, 2, and 3 of the first antibody H chain consist of SEQ ID NOs: 105-107, respectively; 
(a11) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 105, 106 odnosno 107 (H-lanac CDR-područja od Q499);
Absolute structure parameter 0.04(8) 
Parametar apsolutne strukture _0.04(8)
A pharmaceutical composition comprising an antibody of any one of claims 1 to 5 and/or a conjugate of claim 7, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat sukladno patentnom zahtjevu 3 i farmaceutski prihvatljiv nosač.
Detailed description of the invention The present invention is directed to a ruminant compound feed according to the appended claims, which in addition to conventional feed raw materials contains inside and on the surface of the feed raw material particles a fatty acid mixture wherein the content of saturated free fatty acids is at least 90 %, and the total amount of the fatty acid mixture in the feed is higher than 10 % by weight. 
Životinjska hrana koja sadrži konvencionalne sastojke životinjske hrane i konvencionalne aditive i druga pomoćna sredstva, naznačeno time da životinjska hrana sadrži unutar i na površini hrane čestice sirovog materijala koji sadrži bjelančevine i ugljikohidrate, mješavinu masnih kiselina u iznosu od 1 do 10% težine životinjske hrane, naznačeno time da je udio zasićenih masnih kiselina u mješavini masnih kiselina veći od 90%, te da mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
The combination as defined in Claim 3 wherein the anti-obesity agent is at least one agent selected from the group consisting of a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin reuptake inhibitor, a thyroid receptor beta drug, a 5HT2C agonist, an MCHR1 antagonist, a melanocortin receptor agonist, a melanin-concentrating hormone receptor antagonist, a galanin receptor modulator, an aorexin antagonist, a CCK agonists, an NPY1 or NPY5 antagonist, an NPY2 or NPY4 modulator, a corticotropin releasing factor agonist, a histamine receptor-3 (H3) modulator, a 11-beta-HSD-1 inhibitor, a adinopectin receptor modulator, a monoamine reuptake inhibitor, a ciliary neurotrophic factor, a brain-derived neurotrophic factor, leptin or leptin receptor modulators, a cannabinoid-1 receptor antagonist and an anorectic agent. 
Kombinacija prema patentnom zahtjevu 3, naznačena time što je sredstvo protiv debljine najmanje jedno sredstvo izabrano iz grupe koju čine beta 3 adrenergični agonist, inhibitor lipaze, inhibitor ponovnog preuzimanja serotonina, lijek koji se veže za beta tiroidni receptor, SHT2C agonist, MCHRI antagonist, agonist receptora za melanokortin, antagonist receptora za melanin-koncentrirajući hormon, modulator receptora za galanin, antagonist aoreksina, CCK antagonisti, NPY1 ili NPY5 antagonist, NPY2 ili NPY4 modulator, antagonist faktora oslobađanja kortikotropina, modulator histaminskog receptora-3 (H3), 11-beta-HSD-1 inhibitor, modulator receptora za adinopektin, inhibitor ponovnog preuzimanja monoamina, cilijarni neurotrofni faktor, neurotrofni faktor izveden iz mozga, modulatori leptina ili receptora za leptin, antagonist kanabinoidnog-1 receptora i anorektično sredstvo.
In particular embodiments, R6 is ethyl, propyl, isopropyl or isobutyl. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što R* je etil, propil, izopropil ili izobutil.
The emulsion of claim 1, wherein the low HLB non-ionic hydrophilic surfactant is present at a concentration of 2.5% to 4% expressed as a weight by volume of emulsion (w/v). 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je neionski hidrofilni tenzid niske HLB-vrijednosti prisutan s koncentracijom od 1% do 8% izraženom kao masa po volumenu emulzije (masa/volumen).
Composition of claim 43, wherein said patient is suffering from ovarian carcinoma. 
Oblik prema zahtjevu 43, gdje taj bolesnik boluje od karcinoma jajnika.
The wire fence according to claim 3, wherein the hinge joint (20, 16') of an interior wire line (12i) is formed with end portions of two intersecting transverse wires (14i-1, 14i) coming from respective adjacent line wires. 
Žičana ograda u skladu s patentnim zahtjevom 3, naznačena time što je zglobni spoj (20, 16") unutarnje linijske žice (12;) načinjen s krajnjim dijelovima dvije ukrižene poprečne žice (14;,, 14) koji izlaze iz odgovarajućih susjednih linijskih žica.
The door closer according to claim 1, wherein said at least one first front face and at least one first contact surface are substantially parallel to each other in said closed door position and substantially perpendicular to each other in said open door position, said at least one second front face and at least one second contact surface being substantially perpendicular to each other in said closed door position and substantially parallel to each other in said open door position. 
Spojnica za zatvaranje vrata prema zahtjevu 5, gdje su to barem jedno prvo prednje lice (35", 36") i barem jedna prva kontaktna površina (37", 38") u biti međusobno paralelni u zatvorenom položaju vrata i u biti međusobno okomiti u položaju otvorenih vrata, barem jedno drugo prednje lice (45") i barem jedna druga kontaktna površina (46") su u biti međusobno okomiti u zatvorenom položaju vrata 1 u biti međusobno paralelni u položaju otvorenih vrata.
The assay plate is incubated at room temperature on a shaker for 15 minutes. 
Pokusna pločica je inkubirana 15 minuta pri sobnoj temperaturi na mućkalici.
A method according to claim 6, wherein the disease or condition is asthma or chronic obstructive pulmonary disease (COPD). A method according claim 6, wherein said subject is a human. 
Pripravak za primjenu prema zahtjevu 8 ili 9, naznačen time, što je bolest 1li stanje astma ili kronična opstruktivna plućna bolest (COPD).
Such a surface relief may be a hologram, a grating, a picture or any other kind of surface relief. 
Takav plošni reljef može biti hologram, raster, slika ili bilo kakva druga vrsta plošnog reljefa.
When expressed, this methionine is cleaved without intervention, leaving the natural human N-terminus residue of alanine (e.g. 
Kada se eksprimira, ovaj se metionin cijepa bez intervencije, ostavljajući prirodni humani N-terminalni ostatak alanina (na pr.
or R2 is cycloalkyl and R3 and R4 together with the nitrogen atom to which they are attached form piperidinyl or piperidinylamine; 
ili R2 je cikloalkil te R3 i R4 zajedno s atomom dušika na kojega su priključeni, tvore piperidinil ili piperidinilamin;
The resulting crude is triturated with ice cold water (20 ml) and sonicated. 
Dobiveni sirov proizvod se triturira s ledeno hladnom vodom (20 ml) i izloži ultrazvuku.
A therapeutic agent or prophylactic agent for cognitive disorders comprising, as an active ingredient, an antibody that participates in antigen-antibody reaction with tau protein that has been phosphorylated on at least one amino acid residue present among positions 410 to 421 of the tau protein represented by SEQ ID NO: 1. 
Terapeutski agens ili profilaktički agens za uporabu u postupku liječenja ili prevencije tauopatije, pri čemu terapeutski agens ili profilaktički agens sadrži, kao aktivni sastojak, monoklonsko antitijelo koje se specifično veže na tau protein fosforiliran na ostatku aminokiseline koji odgovara Ser413 od SEQ ID NO: 1, pri čemu je vezanje definirano afinitetom predstavljenim ravnotežnom konstantom disocijacije (KD) od najviše 1 x 10-6 M, i pri čemu je spomenuto vezanje na fosforilirani tau protein barem 10 puta jače od vezanja na tau protein koji nije bio fosforiliran na spomenutom Ser413.
According to a fourteenth aspect, in the method of the eighth aspect, the same firing signal, warm data, and address data are communicated to the plurality of nozzle groups and a unique firing signal is sent to each of the plurality of nozzle groups. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se isti okidni signal, podatke o grijanju i adresne podatke šalje u više skupina mlaznica, gdje se jedinstveni okidni signal šalje u svaku od više skupina mlaznica.
Calculate the Colour Intensity of the material as follows: EPMATHMARKEREP 
Izračuna se intenzitet boje materijala kako slijedi:
A pharmaceutical composition for use in a method of therapy, comprising an antibody which binds to the extracellular portion of a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting of: 
PATENTNI ZAHTJEVI Farmaceutski pripravak za primjenu u postupku liječenja, koja se sastoji od antitijela koje se veže za ekstracelularni dio antigena povezanog s tumorom, Navedeni s tumorom povezani antigen koji ima sekvencu koju kodira nukleinska kiselina koja se odabire iz skupine sastavljene od:
Container (1) according to one of the preceding claims, characterized in that the container (1) is for beverages. 
Spremnik (1) prema patentnom zahtjevu 1, naznačen time da je spremnik (1) ambalaža za pića.
The device of claims 1-5 or the use of claims 6-11 wherein each sponge has a length of 5 cm and width of 5 cm. 
Naprava iz patentnih zahtjeva 1-4 ili uporaba iz patentnih zahtjeva 5-10 pri čemu svaka spužva ima dužinu od 5 em i širinu od 5 cm.
Use of a micronized calcium carbonate in form of a slurry for remineralization of water, the remineralization comprising a step of injecting gaseous carbon dioxide into feed water, wherein the calcium carbonate has a particle size from 0.1 to 100 µm and a HCl insoluble content from 0.05 to 1.5 wt.-% based on the total weight of the micronized calcium carbonate. 
Uporaba mikroniziranog kalcij karbonata u obliku mulja za remineralizaciju vode, remineralizacija sadrži korak injektiranja plinovitog ugljik dioksida u ulaznu vodu, pri čemu kalcij karbonat ima veličinu čestica od 0.1 do 100 um i HCI netopljivi sadržaj od 0.05 do 1.5 wt-% zasnovano na ukupnoj masi mikroniziranog kalcij karbonata. HR P20151292 T1 22.
System according to claim 3, comprising an audio/video digital signal transmitter for broadcasting digital terrestrial television signals. 
Sustav u skladu s patentnim zahtjevom 3, naznačen time, da sadržava audio/video odašiljač digitalnog signala za emitiranje digitalnih zemaljskih televizijskih signala.